Collectively, these data indicate that APE1 confers Erlotinib resistance by activating the IL‐6/STAT3 signaling, suggesting targeting APE1 as a possible therapeutic target in Erlotinib‐resistant NSCLC. Here, STAT3 is linked to non-small cell lung carcinoma.